SUGATAB® – MV1 / MV2 Tablet

Description

Composition (Each Film-Coated Tablet Contains):

• MV1: Glimepiride 1 mg + Metformin Hydrochloride 500 mg + Voglibose I.P. 0.2 mg

• MV2: Glimepiride 2 mg + Metformin Hydrochloride 500 mg + Voglibose I.P. 0.2 mg

Category: Diabetes Care / Triple Oral Antidiabetic Therapy
Form: Oral Tablet
Pack Size: 10×10 Alu-Alu or Blister Pack

---

Product Description:

SUGATAB® – MV1 / MV2 is a triple fixed-dose oral antidiabetic combination developed for patients with type 2 diabetes mellitus (T2DM) who need enhanced control of fasting, postprandial, and overall blood glucose. It combines:

• Glimepiride (sulfonylurea) to stimulate insulin secretion

• Metformin (biguanide) to improve insulin sensitivity

• Voglibose (alpha-glucosidase inhibitor) to delay carbohydrate absorption

Together, they address three key mechanisms of diabetes progression, making this an ideal therapy for patients with uncontrolled or progressive T2DM.

---

Key Benefits:

• Controls fasting, postprandial, and overall blood glucose

• Reduces HbA1c with low risk of long-term complications

• Triple mechanism of action improves insulin response, utilization, and carb digestion

• Improves beta-cell efficiency and insulin sensitivity

• Once or twice daily dosing depending on physician recommendation

---

How it works:

• Glimepiride enhances insulin release from pancreatic beta cells in a glucose-dependent manner

• Metformin lowers hepatic glucose production and increases insulin sensitivity

• Voglibose slows carbohydrate absorption in the intestines, reducing post-meal sugar spikes

This combination provides comprehensive glycemic control and helps reduce the burden of T2DM progression.

---

How to use:

• Take one tablet twice daily, before main meals, or as advised by your physician

• Swallow whole with a full glass of water — do not crush or chew

• Do not skip meals after taking this medicine

• Monitor blood sugar regularly for best control

---

Safety Advice:

• May cause mild gastrointestinal side effects like bloating or flatulence (due to Voglibose)

• Hypoglycemia may occur — always take with meals and avoid prolonged fasting

• Regular monitoring of blood sugar, kidney function, and liver enzymes is advised

• Avoid alcohol during treatment to reduce risk of lactic acidosis and hypoglycemia

---

Precautions:

• Not for use in type 1 diabetes or diabetic ketoacidosis (DKA)

• Caution in patients with renal or hepatic impairment, gastrointestinal disorders, or elderly

• Not recommended during pregnancy or breastfeeding unless prescribed

• Inform your doctor about all other antidiabetic medications or insulin use

---

Storage:

Store in a cool, dry place below 25°C.
Protect from light and moisture.
Keep out of reach of children.